{"type":"trials","record":{"id":41716,"source_id":"clinicaltrials-gov","external_id":"NCT03023059","title":"Dose Ranging Study of Carbidopa-levodopa","brief_summary":"From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Neovascular AMD, and measure the effects on visual acuity and retinal abnormalities due to \"wet\" (neovascular) AMD. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with Neovascular AMD who are already on treatment with anti-VEGF intraocular injections, and measure the effects on visual acuity, retinal abnormalities due to \"wet\" AMD, and document the number of anti-VEGF injections required during the study.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","enrollment":35,"countries":["United States"],"start_date":"2017-05-02","completion_date":"2020-05-04","last_update_date":"2025-09-12","source_url":"https://clinicaltrials.gov/study/NCT03023059","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":null,"organization":"Snyder, Robert W., M.D., Ph.D., P.C.","interventions":["Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in Best Corrected Visual Acuity by Early Treatment Diabetic Retinopathy Study Chart Visual Scale Testing — From…","Change in Central Retinal (Macular) Thickness — From the start of the study to the end (up to 120 days).","Percent Change in Retinal Fluid From Baseline — From the start of the study to the commonly used timeframe of 6 months…","Treatment Emergent Adverse Events — From the start of the study to the commonly used timeframe of 6 months (~192 days),…"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Age-related Macular Degeneration","Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03023059","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2017-05-02 to 2020-05-04","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.858Z","intervention":["Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet"],"participants":35,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in Best Corrected Visual Acuity by Early Treatment Diabetic Retinopathy Study Chart Visual Scale Testing — From…","Change in Central Retinal (Macular) Thickness — From the start of the study to the end (up to 120 days).","Percent Change in Retinal Fluid From Baseline — From the start of the study to the commonly used timeframe of 6 months…","Treatment Emergent Adverse Events — From the start of the study to the commonly used timeframe of 6 months (~192 days),…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41716","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}